A patient with previously untreated metastatic cervical squamous-cell carcinoma has PD-L1 CPS 5 and is fit for platinum–paclitaxel. Which first-line

Question

A patient with previously untreated metastatic cervical squamous-cell carcinoma has PD-L1 CPS 5 and is fit for platinum–paclitaxel. Which first-line plan matches NICE TA939?

Accepted Answer

Use pembrolizumab plus platinum–paclitaxel, with or without bevacizumab, and stop pembrolizumab by 2 years

Answer

Use pembrolizumab plus bevacizumab without chemotherapy, stopping pembrolizumab after 1 year of response

Answer

Use platinum–paclitaxel alone first, reserving pembrolizumab for progression despite CPS being at least 1

Answer

Use pembrolizumab alone because CPS is at least 1, and continue it indefinitely while disease remains controlled

Answer

Use platinum–paclitaxel plus bevacizumab because CPS below 10 excludes pembrolizumab from first-line treatment

Vaginal Dilator — SCE Medical Oncology MCQ

A patient with previously untreated metastatic cervical squamous-cell carcinoma has PD-L1 CPS 5 and is fit for platinum–paclitaxel. Which first-line plan matches NICE TA939?